Antenatal phenobarbital for the prevention of neonatal intracerebral hemorrhage. 1986

S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland

Forty-six pregnant women less than 35 weeks of gestation were enrolled in a prospective randomized controlled study evaluating the effects of antenatal phenobarbital on neonatal intracerebral hemorrhage. The women were randomly assigned to control (n = 22) or treatment (n = 24) groups; the treatment group received 500 mg of phenobarbital intravenously. The time interval between the dose of phenobarbital and delivery was 5.5 +/- 4.8 hours (mean +/- SD). The infants in the control group (n = 23) and those in the phenobarbital-treated group (n = 25) were comparable regarding birth weight, gestational age, and other obstetric and neonatal risk factors associated with intracerebral hemorrhage. The incidence of intracerebral hemorrhage was 56.5% (13 of 23 infants) in the control group and 32% (eight of 25 infants) in the phenobarbital-treated group (p = 0.08). Moderate or severe hemorrhage was diagnosed in six of 13 control infants and in none of the phenobarbital-treated infants (p less than 0.01). The mortality rate was significantly lower in the phenobarbital-treated group (two of 25 infants) than in the control group (eight of 23 infants; p less than 0.05). Our study suggests that antenatal phenobarbital administration results in a decrease in mortality and in the severity of intracerebral hemorrhage in the preterm neonate.

UI MeSH Term Description Entries
D007226 Infant Mortality Postnatal deaths from BIRTH to 365 days after birth in a given population. Postneonatal mortality represents deaths between 28 days and 365 days after birth (as defined by National Center for Health Statistics). Neonatal mortality represents deaths from birth to 27 days after birth. Neonatal Mortality,Mortality, Infant,Postneonatal Mortality,Infant Mortalities,Mortalities, Infant,Mortalities, Neonatal,Mortalities, Postneonatal,Mortality, Neonatal,Mortality, Postneonatal,Neonatal Mortalities,Postneonatal Mortalities
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D010500 Perinatology The branch of medicine dealing with the FETUS and NEWBORN during the perinatal period. The perinatal period begins with the twenty-eighth week of gestation and ends twenty-eight days after birth. Fetal Medicine,Maternal-Fetal Medicine,Materno-Fetal Medicine,Fetal Medicines,Maternal Fetal Medicine,Maternal-Fetal Medicines,Materno Fetal Medicine,Materno-Fetal Medicines,Medicine, Fetal,Medicine, Maternal-Fetal,Medicine, Materno-Fetal
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002543 Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA. Brain Hemorrhage, Cerebral,Cerebral Parenchymal Hemorrhage,Hemorrhage, Cerebral,Intracerebral Hemorrhage,Hemorrhage, Cerebrum,Brain Hemorrhages, Cerebral,Cerebral Brain Hemorrhage,Cerebral Brain Hemorrhages,Cerebral Hemorrhages,Cerebral Parenchymal Hemorrhages,Cerebrum Hemorrhage,Cerebrum Hemorrhages,Hemorrhage, Cerebral Brain,Hemorrhage, Cerebral Parenchymal,Hemorrhage, Intracerebral,Hemorrhages, Cerebral,Hemorrhages, Cerebral Brain,Hemorrhages, Cerebral Parenchymal,Hemorrhages, Cerebrum,Hemorrhages, Intracerebral,Intracerebral Hemorrhages,Parenchymal Hemorrhage, Cerebral,Parenchymal Hemorrhages, Cerebral
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
February 1987, American journal of obstetrics and gynecology,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
January 1996, Journal of perinatology : official journal of the California Perinatal Association,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
January 1987, Indian journal of pediatrics,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
June 2000, Canadian family physician Medecin de famille canadien,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
August 1997, The New England journal of medicine,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
December 1991, The Journal of pediatrics,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
May 1997, Pediatrics,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
April 1986, Pediatrics,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
February 1987, Pediatrics,
S Shankaran, and E E Cepeda, and N Ilagan, and F Mariona, and M Hassan, and R Bhatia, and E Ostrea, and M P Bedard, and R L Poland
March 1976, Obstetrics and gynecology,
Copied contents to your clipboard!